此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

在未经治疗的套细胞淋巴瘤参与者中比较 Zanubrutinib + Rituximab 与 Bendamustine + Rituximab 的研究 (MANGROVE)

2026年9月25日 更新者:BeOne Medicines

一项比较 Zanubrutinib (BGB-3111) 加利妥昔单抗与苯达莫司汀加利妥昔单抗治疗不适合干细胞移植的先前未治疗的套细胞淋巴瘤患者的 3 期随机、开放标签、多中心研究

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

研究概览

详细说明

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

研究类型

介入性

注册 (实际的)

510

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100044
        • Peking University Peoples Hospital
      • Beijing、Beijing Municipality、中国、100050
        • Beijing Friendship Hospital, Capital Medical University
    • Fujian
      • Fuzhou、Fujian、中国、350001
        • Fujian Medical University Union Hospital
      • Quanzhou、Fujian、中国、362000
        • Quanzhou First Affliated Hospital of Fujian Medical University
    • Guangdong
      • Guangzhou、Guangdong、中国、510080
        • Guangdong Provincial Peoples Hospital
      • Guangzhou、Guangdong、中国、510515
        • Nanfang Hospital of Southern Medical University
      • Guangzhou、Guangdong、中国、510060
        • Sun Yat Sen University Cancer Center
    • Heilongjiang
      • Harbin、Heilongjiang、中国、150000
        • Harbin Medical University Cancer Hospital
    • Henan
      • Zhengzhou、Henan、中国、450000
        • Henan Cancer Hospital
    • Hubei
      • Wuhan、Hubei、中国、430030
        • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    • Hunan
      • Changsha、Hunan、中国、410013
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • Jiangsu Province Hospital
      • Nanjing、Jiangsu、中国、210008
        • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
      • Xuzhou、Jiangsu、中国、221000
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang、Jiangxi、中国、330006
        • The First Affiliated Hospital of Nanchang University Branch Donghu
    • Jilin
      • Changchun、Jilin、中国、130021
        • The First Hospital of Jilin University
      • Changchun、Jilin、中国、130021
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang、Liaoning、中国、110004
        • Shengjing Hospital of China Medical University
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200000
        • Fudan University Shanghai Cancer Center
      • Shanghai、Shanghai Municipality、中国、200120
        • Shanghai East Hospital
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • West China Hospital, Sichuan University
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300060
        • Tianjin Medical University Cancer Institute and Hospital
      • Tianjin、Tianjin Municipality、中国、300020
        • Institute of Hematology and Hospital of Blood Disease
    • Xinjiang
      • Ürümqi、Xinjiang、中国、830000
        • Affiliated Cancer Hospital of Xinjiang Medical University
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310022
        • Zhejiang Cancer Hospital
      • Hangzhou、Zhejiang、中国、310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Ningbo、Zhejiang、中国、315000
        • Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
      • Cherkasy、乌克兰、18009
        • Cherkasy Regional Oncology Dispensary
      • Dnipro、乌克兰、49102
        • Municipal Non Profit Enterprise City Clinical Hospital
      • Kiev、乌克兰、3022
        • National Cancer Institute
      • Lviv、乌克兰、79044
        • Si Institute of Blood Pathology and Transfusion Medicine Nams of Ukraine, Hematology Department
      • Moscow、俄罗斯、142770
        • Gbuz Mmcc Kommunarka Dzm
    • Moscow
      • Moscow、Moscow、俄罗斯、125284
        • Clinical Hospital, Sp Botkin
    • Sankt-Peterburg
      • Saint Petersburg、Sankt-Peterburg、俄罗斯、191024
        • Fgu Russian Scientific Research Institute of Hematology and Transfusiology
      • Saint Petersburg、Sankt-Peterburg、俄罗斯、194291
        • Leningrad Regional Clinic and Hospital
    • Ontario
      • Ottawa、Ontario、加拿大、K1H 8M2
        • The Ottawa Hospital
    • Quebec
      • Sherbrooke、Quebec、加拿大、J1H 5N4
        • Ciusss de Lestrie Chus
      • Tainan、台湾、704
        • National Cheng Kung University Hospital
      • Tainan、台湾、736
        • Chi Mei Hospital Liouying
      • Taipei、台湾、114
        • Tri Service General Hospital
      • Ankara、土耳其(türkiye)、06620
        • Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
      • Ankara、土耳其(türkiye)、6500
        • Gazi University
      • Ankara、土耳其(türkiye)、06700
        • Hematoloji Ve Hematolik Onkoloji Tani Ve Tedavi Merezi
      • Edirne、土耳其(türkiye)、22030
        • Tr Trakya University Health Research and Application Center (Hospital)
      • Istanbul、土耳其(türkiye)、34365
        • Vkv American Hospital
      • Mersin、土耳其(türkiye)、33000
        • Mersin Universitesi Tip Fakultesi Hastanesi
      • Linz、奥地利、4020
        • Ordensklinikum Linz Gmbh Elisabethinen
      • Salzburg、奥地利、5020
        • Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
      • Vienna、奥地利、1090
        • Medical University Vienna Oncology
      • Cologne、德国、50937
        • Uniklinik Koln (Aor)
      • Heidelberg、德国、69120
        • Universitatsklinikum Heidelberg
      • Munich、德国、81377
        • Dept of Medicine Iii, University Hospitallmu
      • Ulm、德国、89081
        • Universitaetsklinikum Ulm, Innere Medizin Iii
      • Wuppertal、德国、42283
        • Petrus Krankenhaus Wuppertal
      • Alessandria、意大利、15121
        • Azienda Ospedaliera Nazionale Ssantonio E Biagio E Cesare Arrigo
      • Bologna、意大利、40138
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Genova、意大利、16132
        • Azienda Ospedaliera Universitaria San Martino
      • Milan、意大利、20162
        • Niguarda Cancer Center Division of Hematology
      • Novara、意大利、28100
        • Aou Maggiore Della Carita
      • Palermo、意大利、90146
        • Aoor Villa Sofia Cervello
      • Pisa、意大利、56126
        • Aou Pisana, Stabilimento Di Santa Chiara
      • Ravenna、意大利、48121
        • Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia
      • Reggio Emilia、意大利、42123
        • Azienda Unita Sanitaria Locale Irccs
      • Roma、意大利、00161
        • Universita Degli Studi La Sapienza
      • Siena、意大利、53100
        • Aou Senese Policlinico Santa Maria Alle Scotte
      • Torino、意大利、10126
        • Ao Citta Della Salute E Della Scienza Di Torino Presidio O
      • Verona、意大利、37142
        • University of Verona
      • Christchurch、新西兰、8011
        • Christchurch Hospital (Canterbury Health Laboratories)
      • Tauranga、新西兰、3112
        • Tauranga Hospital
      • Yokohama、日本、221-0855
        • Yokohama Municipal Citizens Hospital
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、460-0001
        • National Hospital Organization Nagoya Medical Center
      • Toyohashi、Aichi-ken、日本、441-8570
        • Toyohashi Municipal Hospital
    • Chiba
      • Chiba、Chiba、日本、260-8717
        • Chiba Cancer Center
    • Fukuoka
      • Kurume、Fukuoka、日本、830-0011
        • Kurume University Hospital
    • Hiroshima
      • Hiroshima、Hiroshima、日本、730-8619
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Kanagawa
      • Yokohama、Kanagawa、日本、241-8515
        • Kanagawa Cancer Center
    • Kumamoto
      • Kumamoto、Kumamoto、日本、860-0008
        • National Hospital Organization Kumamoto Medical Center
    • Kyoto
      • Kyoto、Kyoto、日本、602-8566
        • University Hospital, Kyoto Prefectural Univ of Medicine
    • Miyagi
      • Sendai、Miyagi、日本、980-8574
        • Tohoku University Hospital
    • Okayama-ken
      • Kurashikishi、Okayama-ken、日本、710-8602
        • Kurashiki Central Hospital
      • Okayama、Okayama-ken、日本、701-1192
        • National Hospital Organization Okayama Medical Center
    • Osaka
      • Osaka、Osaka、日本、545-8586
        • Osaka Metropolitan University Hospital
      • Osakashi、Osaka、日本、543-8555
        • Osaka Red Cross Hospital
    • Tokyo
      • Chuoku、Tokyo、日本、104-0045
        • National Cancer Center Hospital
      • Tokyo、Tokyo、日本、113-8519
        • Tokyo Medical and Dental University Hospital
      • Bruges、比利时、8000
        • Az Sint Jan Brugge
      • Brussels、比利时、1090
        • Universitair Ziekenhuis Brussel
      • Edegem、比利时、2650
        • Uz Antwerpen
      • Kortrijk、比利时、8500
        • Az Groeninge Campus Loofstraat
      • Liège、比利时、4000
        • Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman
      • Yvoir、比利时、5530
        • Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne
      • Bordeaux、法国、33076
        • Centre de Lutte Contre Le Cancer Institut Bergonie
      • Brest、法国、29200
        • Chru de Brest Hospital Morvan
      • Dijon、法国、J4V 2H1
        • Chu Dijon
      • Grenoble、法国、38043
        • Chu Grenoble Alpes
      • Le Mans、法国、72037
        • Centre Hospitalier Le Mans
      • Lille、法国、59000
        • Hopital Claude Huriez Chu Lille
      • Marseille、法国、13009
        • Institut Paoli Calmettes
      • Nantes、法国、44093
        • Centre Hospitalier Universitaire Nantes Hotel Dieu
      • Paris、法国、75005
        • Institut Curie
      • Paris、法国、75015
        • Necker University Hospital
      • PierreBenite、法国、69495
        • Chu Hopital Lyon Sud
      • Poitiers、法国、86000
        • Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard
      • Quimper、法国、29000
        • Ch Cornouaille
      • Toulouse、法国、31059
        • Iuc Toulouse Oncopole
      • Bydgoszcz、波兰、85-168
        • Szpital Uniwersytecki Nr Im Dr Jana Biziela
      • Chorzów、波兰、41-503
        • Silesian Healthy Blood Clinic
      • Gdansk、波兰、80-952
        • Uniwersyteckie Centrum Kliniczne
      • Gdask、波兰、80-219
        • Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii
      • Gdynia、波兰、81-519
        • Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
      • Krakow、波兰、30-727
        • Pratia McM Krakow
      • Legnica、波兰、59-220
        • Wojewodzki Szpital Specjalistyczny W Legnicy
      • Lodz、波兰、93-510
        • Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin、波兰、20-090
        • Centrum Onkologii Ziemi Lubelskiej
      • Warsaw、波兰、02-776
        • Instytut Hematologii I Transfuzjologii W Warszawie
      • Wałbrzych、波兰、58-309
        • Specjalistyczny Szpital Im Dr Alfreda Sokolowskiego
      • Wroclaw、波兰、50-556
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
    • Australian Capital Territory
      • Garran、Australian Capital Territory、澳大利亚、2605
        • Canberra Hospital
    • New South Wales
      • Concord、New South Wales、澳大利亚、2139
        • Concord Repatriation General Hospital
      • Cudgen、New South Wales、澳大利亚、2487
        • The Tweed Valley Hospital
      • Darlinghurst、New South Wales、澳大利亚、2010
        • Saint Vincents Hospital Sydney
      • Gosford、New South Wales、澳大利亚、2250
        • Gosford Hospital
      • Waratah、New South Wales、澳大利亚、2298
        • Calvary Mater Newcastle
    • Queensland
      • Birtinya、Queensland、澳大利亚、4575
        • Sunshine Coast Hospital and Health Service
      • South Brisbane、Queensland、澳大利亚、4101
        • Icon Cancer Foundation
    • South Australia
      • Bedford PK、South Australia、澳大利亚、5042
        • Flinders Medical Centre
    • Tasmania
      • Hobart、Tasmania、澳大利亚、7000
        • Royal Hobart Hospital
    • Victoria
      • Clayton、Victoria、澳大利亚、3168
        • Monash Health
      • Fitzroy、Victoria、澳大利亚、3065
        • St Vincents Hospital Melbourne
      • Frankston、Victoria、澳大利亚、3199
        • Peninsula Private Hospital
      • Geelong、Victoria、澳大利亚、3220
        • Barwon Health the Geelong Hospital
    • Western Australia
      • Perth、Western Australia、澳大利亚、6000
        • Royal Perth Hospital
      • Cork、爱尔兰、t12DC4A
        • Cork University Hospital
      • Dublin、爱尔兰、D7
        • Mater Misericordiae University Hospital
      • Dublin、爱尔兰、D8
        • St Jamess Hospital
      • Galway、爱尔兰、H91 YR71
        • University Hospital Galway
      • Limerick、爱尔兰、V94F858
        • University Hospital Limerick
      • Waterford、爱尔兰、X91 ER8E
        • University Hospital Waterford
      • Bucharest、罗马尼亚、022328
        • Institutul Clinic Fundeni
      • Iași、罗马尼亚、700483
        • Institutul Regional de Oncologie Iasi
    • California
      • Orange、California、美国、92868
        • Chao Family Comprehensive Cancer Center
    • Illinois
      • Chicago、Illinois、美国、60612
        • Rush University Medical Center
    • Massachusetts
      • Boston、Massachusetts、美国、02215-5400
        • Beth Israel Deaconess Medical Center (Bidmc)
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan Health System
    • Nevada
      • Las Vegas、Nevada、美国、89169
        • Comprehensive Cancer Centers of Nevada
    • New York
      • New York、New York、美国、10029
        • Icahn School of Medicine At Mount Sinai
      • Westbury、New York、美国、11590
        • Clinical Research Alliance, Inc
    • Oregon
      • Portland、Oregon、美国、97213
        • Providence Portland Medical Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15224
        • West Penn Hospital
    • Texas
      • Houston、Texas、美国、77030-4009
        • The University of Texas Md Anderson Cancer Center
      • Lubbock、Texas、美国、79410
        • Joe Arrington Cancer Research and Treatment Center
    • Washington
      • Seattle、Washington、美国、98109
        • Seattle Cancer Care Alliance
      • Abergavenny、英国、NP7 7EG
        • Aneurin Bevan University Health Board
      • Birmingham、英国、B9 5SS
        • Birmingham Heartlands Hospital
      • Dudley、英国、DY1 2HQ
        • Russells Hall Hopsital
      • Sutton、英国、SM2 5PT
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
      • Goes、荷兰、4462 RA
        • Admiraal de Ruijter Ziekenhuis
      • Groningen、荷兰、9713 GZ
        • University of Medical Center Groningen (Umcg)
      • Nieuwegein、荷兰、3435 CM
        • St Antonius Ziekenhuis, Randd Interne Geneeskunde (F)
      • Nijmegen、荷兰、6525 GA
        • Albert Schweitzer Ziekenhuis
      • Rotterdam、荷兰、3015 GD
        • Erasmus Mc
      • The Hague、荷兰、2545 CH
        • Hagaziekenhuis
      • Lisbon、葡萄牙、1099-023
        • Instituto Portugues Oncologia de Lisboa Francisco Gentil, Epe
      • Lisbon、葡萄牙、1649-035
        • Chuln Hospital de Santa Maria
      • Porto、葡萄牙、4099-001
        • Centro Hospitalar Universitario Porto
      • Porto、葡萄牙、4200-072
        • Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe
      • Barcelona、西班牙、08035
        • Hospital Universitario Vall Dhebron
      • Barcelona、西班牙、08916
        • Ico Hug Trias I Pujol
      • Barcelona、西班牙、08908
        • Institut Catala Doncologia
      • Girona、西班牙、17007
        • Ico Girona
      • Madrid、西班牙、28046
        • Hospital Universitario La Paz
      • Madrid、西班牙、28040
        • Start Madrid Fundacion Jimenez Diaz
      • Madrid、西班牙、28033
        • Md Anderson Cancer Center Madrid Spain
      • Madrid、西班牙、28009
        • Hospital Universitario Gregorio Maranon
      • Málaga、西班牙、29010
        • Hospital Regional Universitario de Malaga
      • Seville、西班牙、41013
        • Hospital Universitario Virgen Del Rocio

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  1. ≥70 years of age at the time of informed consent, OR ≥60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
  2. Histologically confirmed diagnosis of MCL
  3. No prior systemic treatments for MCL
  4. Measurable disease by CT/MRI
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  6. Adequate marrow and organ function

Key Exclusion Criteria:

  1. Known central nervous system involvement by lymphoma
  2. Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
  3. Clinically significant cardiovascular disease
  4. History of severe bleeding disorder
  5. Unable to swallow capsules or disease significantly affecting gastrointestinal function
  6. Active fungal, bacterial and/or viral infection requiring systemic therapy
  7. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm A: zanubrutinib plus rituximab

Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression.

Administered as two 80 mg capsules by mouth twice a day

其他名称:
  • 布鲁金萨
  • BGB-3111

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

有源比较器:Arm B: bendamustine plus rituximab

Participants will receive bendamustine plus rituximab, followed by observation.

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free survival (PFS) determined by independent central review
大体时间:Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years

次要结果测量

结果测量
措施说明
大体时间
PFS by investigator assessment
大体时间:Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years
Overall response rate (ORR)
大体时间:Up to approximately 7 years

ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment.

Up to approximately 7 years
Duration of response (DOR)
大体时间:Up to approximately 7 years

DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first.

Up to approximately 7 years
Overall survival (OS)
大体时间:Up to approximately 7 years

OS is defined as the time from randomization to the date of death due to any reason.

Up to approximately 7 years
Time to Response (TTR)
大体时间:Up to approximately 7 years

TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response.

Up to approximately 7 years
Rate of complete response (CR) or complete metabolic response
大体时间:Up to approximately 7 years

Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment.

Up to approximately 7 years
Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L)
大体时间:Up to approximately 7 years

EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.

Up to approximately 7 years
PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
大体时间:Up to approximately 7 years

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).

Up to approximately 7 years
Number of participants with adverse events and serious adverse events
大体时间:Up to approximately 7 years

Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings.

Up to approximately 7 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Study Director、BeOne Medicines

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年8月20日

初级完成 (实际的)

2026年4月27日

研究完成 (估计的)

2031年9月30日

研究注册日期

首次提交

2019年6月27日

首先提交符合 QC 标准的

2019年6月27日

首次发布 (实际的)

2019年6月28日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月25日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

IPD 共享时间框架

See plan description

IPD 共享访问标准

See plan description

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅